Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 49
Filtrar
1.
BJOG ; 131(7): e1-e30, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38311315

RESUMEN

An objective and validated index of nausea and vomiting such as the Pregnancy-Unique Quantification of Emesis (PUQE) and HyperEmesis Level Prediction (HELP) tools can be used to classify the severity of NVP and HG. [Grade C] Ketonuria is not an indicator of dehydration and should not be used to assess severity. [Grade A] There are safety and efficacy data for first line antiemetics such as anti (H1) histamines, phenothiazines and doxylamine/pyridoxine (Xonvea®) and they should be prescribed initially when required for NVP and HG (Appendix III). [Grade A] There is evidence that ondansetron is safe and effective. Its use as a second line antiemetic should not be discouraged if first line antiemetics are ineffective. Women can be reassured regarding a very small increase in the absolute risk of orofacial clefting with ondansetron use in the first trimester, which should be balanced with the risks of poorly managed HG. [Grade B] Metoclopramide is safe and effective and can be used alone or in combination with other antiemetics. [Grade B] Because of the risk of extrapyramidal effects metoclopramide should be used as second-line therapy. Intravenous doses should be administered by slow bolus injection over at least 3 minutes to help minimise these. [Grade C] Women should be asked about previous adverse reactions to antiemetic therapies. If adverse reactions occur, there should be prompt cessation of the medications. [GPP] Normal saline (0.9% NaCl) with additional potassium chloride in each bag, with administration guided by daily monitoring of electrolytes, is the most appropriate intravenous hydration. [Grade C] Combinations of different drugs should be used in women who do not respond to a single antiemetic. Suggested antiemetics for UK use are given in Appendix III. [GPP] Thiamine supplementation (either oral 100 mg tds or intravenous as part of vitamin B complex (Pabrinex®)) should be given to all women admitted with vomiting, or severely reduced dietary intake, especially before administration of dextrose or parenteral nutrition. [Grade D] All therapeutic measures should have been tried before considering termination of pregnancy. [Grade C].


Asunto(s)
Antieméticos , Hiperemesis Gravídica , Ondansetrón , Humanos , Femenino , Embarazo , Hiperemesis Gravídica/terapia , Hiperemesis Gravídica/diagnóstico , Antieméticos/uso terapéutico , Antieméticos/administración & dosificación , Ondansetrón/uso terapéutico , Ondansetrón/administración & dosificación , Náuseas Matinales/terapia , Náusea/etiología , Náusea/terapia , Piridoxina/uso terapéutico , Piridoxina/administración & dosificación , Metoclopramida/uso terapéutico , Metoclopramida/administración & dosificación , Índice de Severidad de la Enfermedad , Complicaciones del Embarazo/tratamiento farmacológico , Complicaciones del Embarazo/terapia
2.
Pediatrics ; 146(Suppl 1): S93-S98, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32737240

RESUMEN

A central tension in pediatric research ethics arises from our desire to protect children from harm while also allowing progress toward discoveries that could improve child health. A prime example of this tension is research on a controversial yet increasingly common practice: the use of cannabis by women to treat nausea and vomiting of pregnancy. Studies of cannabis use in pregnancy face a combination of ethical hurdles because of the inclusion of pregnant women and involvement of a schedule I controlled substance. Given the growing need for research on the safety and efficacy of cannabis for nausea and vomiting of pregnancy, we reflect on the multiple historical contexts that have contributed to the challenge of studying cannabis use during pregnancy and make a case for the ethical rationale for such research.


Asunto(s)
Ética en Investigación , Marihuana Medicinal/uso terapéutico , Náuseas Matinales/terapia , Pediatría/ética , Mujeres Embarazadas , Sujetos de Investigación , Antieméticos/efectos adversos , Diciclomina/uso terapéutico , Doxilamina/uso terapéutico , Aprobación de Drogas , Combinación de Medicamentos , Femenino , Humanos , Marihuana Medicinal/efectos adversos , Ondansetrón/uso terapéutico , Embarazo , Piridoxina/uso terapéutico , Teratógenos , Talidomida/efectos adversos
3.
J Complement Integr Med ; 17(2)2020 Jan 23.
Artículo en Inglés | MEDLINE | ID: mdl-31971914

RESUMEN

Background Nausea and vomiting of pregnancy (NVP) is the most common problem for women in early pregnancy. The present study was conducted to compare the effect of pressure on KID21 and P6 on the severity of NVP. Methods This single-blind clinical trial was conducted on pregnant women in their first trimester with NVP, referring to the clinic of Ayatollah Rouhani Hospital of Babol, Iran, in 2017. Eighty-two participants were randomly divided into KID21 and P6 pressure groups. The researcher applied pressure on these two points 20 min each day for four consecutive days. The severity of nausea and vomiting was then assessed using the visual analog scale (VAS) by the patient and counting its frequency in 24 h, respectively. Finally, the collected data were analyzed using SPSS 22 by repeated measures ANOVA and paired sample T-Test. Results The severity of NVP in the 82 participating pregnant women decreased in both groups (p<0.001), and there was no significant difference between the two groups in terms of the severity of NVP (p=0.68), although the reduction in nausea was greater in the P6 group than KID21 group, and the reduction in vomiting was greater in the KID21 group than the P6 group. Effect size for vomiting and nausea was 0.28 and 0.16, respectively. No side-effects were observed in the two groups during these four days. Conclusions Pressure on P6 and KID21 points has no advantage over each other in the treatment of NVP, but acupressure is an effective, complication-free, inexpensive and accessible treatment for this complication.


Asunto(s)
Acupresión/métodos , Náuseas Matinales/terapia , Adulto , Femenino , Humanos , Embarazo , Método Simple Ciego , Encuestas y Cuestionarios , Adulto Joven
4.
J Obstet Gynaecol ; 40(1): 10-19, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31215276

RESUMEN

To assess the efficacy alternative medicine in the treatment of nausea and vomiting of pregnancy (NVP), three major databases of PubMed, Cochrane Library and Scopus were systematically searched since inception until January 14 2019 to investigate the effects of herbal medicines on NVD. The quality assessment of studies was performed according to Jadad scale. All studies showed that ginger had a positive effect on nausea in pregnant women. Unlike others studies, one study reported that ginger was not beneficial to the treatment of vomiting. Herbal medicines such as matricaria chamomilla, elettaria cardamomum, pomegranate and spearmint syrup, lemon provide safe and effective medical alternatives for treating pregnant women with mild to moderate NVD. The results suggested that ginger were more effective than vitamin B, but at the dose of 35-500 mg ginger, vitamin B6 and ginger had identical effect. However, over a longer treatment period (60 days), vitamin B6 was proved to be more effective than ginger. The same effect was observed in the comparison of quince and vitamin B6 as well as ginger and doxylamine plus pyridoxine. Mentha did not generated a positive effect on nausea and vomiting. However, this finding should be considered in the light of the above limitations.IMPACT STATEMENTWhat is already known on the subject? Previous systematic reviews have shown the superiority of ginger over the placebo. Lemon, chamomile and Mentha have been found to be more effective than the placebo.What do the results of this study add? This systematic review confirmed the results of previous systematic reviews in a larger sample size. Ginger was more effective than vitamin B, but at the dose of 35-500 mg ginger, vitamin B6 and ginger had identical effect. However, over a longer treatment period (60 days), vitamin B6 was proved to be more effective than ginger.What are the implications of these findings for clinical practice and further research? Matricaria chamomilla, elettaria cardamomum, pomegranate and spearmint syrup, lemon and ginger can be recommended to pregnant women for alleviation of NVP.


Asunto(s)
Antieméticos/uso terapéutico , Terapias Complementarias/métodos , Náuseas Matinales/terapia , Fitoterapia/métodos , Extractos Vegetales/uso terapéutico , Adulto , Femenino , Zingiber officinale , Humanos , Matricaria , Embarazo , Resultado del Tratamiento , Vitamina B 6/uso terapéutico , Complejo Vitamínico B/uso terapéutico
5.
BMJ Open ; 9(9): e031593, 2019 09 08.
Artículo en Inglés | MEDLINE | ID: mdl-31501131

RESUMEN

OBJECTIVE: Childbirth is suggested to be associated with elevated levels of sickness absence (SA) and disability pension (DP). However, detailed knowledge about SA/DP patterns around childbirth is lacking. We aimed to compare SA/DP across different time periods among women according to their childbirth status. DESIGN: Register-based longitudinal cohort study. SETTING: Sweden. PARTICIPANTS: Three population-based cohorts of nulliparous women aged 18-39 years, living in Sweden 31 December 1994, 1999 or 2004 (nearly 500 000/cohort). PRIMARY AND SECONDARY OUTCOME MEASURES: Sum of SA >14 and DP net days/year. METHODS: We compared crude and standardised mean SA and DP days/year during the 3 years preceding and the 3 years after first childbirth date (Y-3 to Y+3), among women having (1) their first and only birth during the subsequent 3 years (B1), (2) their first birth and at least another delivery (B1+), and (3) no childbirths during follow-up (B0). RESULTS: Despite an increase in SA in the year preceding the first childbirth, women in the B1 group, and especially in B1+, tended to have fewer SA/DP days throughout the years than women in the B0 group. For cohort 2005, the mean SA/DP days/year (95% CIs) in the B0, B1 and B1+ groups were for Y-3: 25.3 (24.9-25.7), 14.5 (13.6-15.5) and 8.5 (7.9-9.2); Y-2: 27.5 (27.1-27.9), 16.6 (15.5-17.6) and 9.6 (8.9-10.4); Y-1: 29.2 (28.8-29.6), 31.4 (30.2-32.6) and 22.0 (21.2-22.9); Y+1: 30.2 (29.8-30.7), 11.2 (10.4-12.1) and 5.5 (5.0-6.1); Y+2: 31.7 (31.3-32.1), 15.3 (14.2-16.3) and 10.9 (10.3-11.6); Y+3: 32.3 (31.9-32.7), 18.1 (17.0-19.3) and 12.4 (11.7-13.0), respectively. These patterns were the same in all three cohorts. CONCLUSIONS: Women with more than one childbirth had fewer SA/DP days/year compared with women with one childbirth or with no births. Women who did not give birth had markedly more DP days than those giving birth, suggesting a health selection into childbirth.


Asunto(s)
Náuseas Matinales , Parto , Pensiones/estadística & datos numéricos , Atención Prenatal , Ausencia por Enfermedad , Adulto , Orden de Nacimiento , Estudios de Cohortes , Femenino , Humanos , Estudios Longitudinales , Náuseas Matinales/economía , Náuseas Matinales/epidemiología , Náuseas Matinales/terapia , Embarazo , Atención Prenatal/métodos , Atención Prenatal/estadística & datos numéricos , Sistema de Registros/estadística & datos numéricos , Ausencia por Enfermedad/economía , Ausencia por Enfermedad/estadística & datos numéricos , Ausencia por Enfermedad/tendencias , Suecia/epidemiología
6.
Emerg Med Clin North Am ; 37(2): 219-237, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30940368

RESUMEN

Early in pregnancy women frequently experience nausea, vomiting, and vaginal bleeding. Nausea and vomiting can be mild, managed by dietary modifications and medications, or severe, requiring intravenous fluids and medications. Care should be used when selecting medications for nausea to avoid additional side effects or potential harm to the developing fetus. When evaluating vaginal bleeding in early pregnancy, ectopic pregnancy must be ruled out. If an intrauterine pregnancy is seen, threatened miscarriage should be considered and the patient appropriately counseled. If neither intrauterine pregnancy nor ectopic pregnancy can be established, a management algorithm for pregnancy of unknown location is presented.


Asunto(s)
Complicaciones del Embarazo/diagnóstico , Primer Trimestre del Embarazo , Aborto Espontáneo/diagnóstico , Aborto Espontáneo/terapia , Servicio de Urgencia en Hospital , Femenino , Humanos , Náuseas Matinales/diagnóstico , Náuseas Matinales/terapia , Embarazo , Complicaciones del Embarazo/terapia , Embarazo Ectópico/diagnóstico , Embarazo Ectópico/terapia , Hemorragia Uterina/complicaciones , Hemorragia Uterina/diagnóstico
8.
Laeknabladid ; 105(1): 19-21, 2019 Jan.
Artículo en Islandés | MEDLINE | ID: mdl-30601123

RESUMEN

A woman in her thirties, 15 weeks pregnant, underwent acupuncture therapy because of pregnancy-related nausea and vomiting. Several hours later she experienced shortness of breath and therefore came to the emergency room. Physical examination revealed tachypnea and reduced breath sounds bilaterally but normal oxygen saturation and blood pressure. Chest X-ray showed bilateral subtotal pneumo-thoraces. Chest tubes were inserted into both pleural cavities and the patient recovered successfully and was discharged in good health 3 days after admission. This case report emphasizes the risks of acupuncture to the chest cavity that in this case resulted in bi---- l-ateral pneumothoraces, a condition that can become life threatening in this case to both mother and fetus.


Asunto(s)
Terapia por Acupuntura/efectos adversos , Náuseas Matinales/terapia , Neumotórax/etiología , Adulto , Tubos Torácicos , Femenino , Humanos , Neumotórax/diagnóstico por imagen , Neumotórax/terapia , Embarazo , Segundo Trimestre del Embarazo , Resultado del Tratamiento
10.
Expert Rev Clin Pharmacol ; 11(11): 1143-1150, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30261764

RESUMEN

INTRODUCTION: Several drugs were explored for their utility in treating nausea and vomiting in pregnancy (NVP). The present study is a network meta-analysis of such drugs. METHODS: Electronic databases were searched for randomized clinical trials that have compared active interventions (with placebo or other active interventions) for treating NVP. Nausea scores were the primary outcome and changes in nausea scores, emetic episodes, adverse events, and vomiting control were the key secondary outcomes. Weighted mean difference was the effect estimate for continuous variable and odds ratio for the numerical variable. Random-effects model was used and the strength of the evidence was graded. RESULTS: Fifty studies were included in the systematic review and 42 in the meta-analysis. Acupuncture, chamomile, dimenhydrinate, doxylamine/vitamin B6, ginger, quince, metoclopramide, and vitamin B6 were associated with reduced nausea scores compared to placebo. Of these interventions, ginger and vitamin B6 were also associated with better vomiting control and less incidence of adverse events. Adequate evidence supporting the use exists only for ginger and the quality of evidence for this comparison is moderate. Strength of evidence for all other comparisons is very low. CONCLUSION: Present evidence is conclusive on the therapeutic benefits of ginger in treating NVP. Although favorable results were obtained for several other interventions, the strength of evidence is very low. The results of this network meta-analysis should be interpreted with extreme caution as it might change with the advent of data from future head-to-head clinical trials.


Asunto(s)
Antieméticos/uso terapéutico , Hiperemesis Gravídica/terapia , Náuseas Matinales/terapia , Terapia por Acupuntura/métodos , Antieméticos/efectos adversos , Femenino , Zingiber officinale/química , Humanos , Metaanálisis en Red , Embarazo , Ensayos Clínicos Controlados Aleatorios como Asunto , Vitamina B 6/uso terapéutico
11.
J Obstet Gynaecol Res ; 43(4): 662-668, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28418209

RESUMEN

AIM: To evaluate the efficacy of acupressure at the Neiguan point (Pericardium [P]6) as adjuvant treatment during inpatient management of severe nausea and vomiting in pregnancy. METHODS: Low risk, spontaneously conceived singleton pregnancies were randomly assigned to a treatment group, who received an acupressure band placed at the Neiguan point (P6) or a placebo group who received an otherwise identical non-stimulating wristband. Participants wore the band for 12 h daily for the first three days of admission. The primary outcome measure was the severity of symptoms of nausea, vomiting and retching, recorded according to Pregnancy-Unique Quantification of Emesis and Nausea score. RESULTS: There was a statistically significant improvement in Pregnancy-Unique Quantification of Emesis and Nausea scores from day 1 until day 3 of admission in the treatment group compared with the placebo. Patients who received Neiguan point acupressure also showed a significant improvement in their ketonuria scores. The treatment group required a shorter hospital stay compared with the placebo. The only reported side effect of the acupressure band was redness on the wrist. CONCLUSIONS: The use of the acupressure band at the Neiguan point (P6) for 12 h daily for three days for inpatients with hyperemesis gravidarum significantly reduced the symptoms of nausea, vomiting and retching and ketonuria and led to a reduction in hospital stay. We recommend the use of the acupressure band at the Neiguan point (P6) as an adjunct/supplementary therapy to co-exist with the standard care of management for hyperemesis gravidarum, particularly in low-risk pregnant women.


Asunto(s)
Acupresión/métodos , Náuseas Matinales/terapia , Evaluación de Procesos y Resultados en Atención de Salud , Acupresión/instrumentación , Adulto , Método Doble Ciego , Femenino , Humanos , Embarazo
12.
Med Hypotheses ; 95: 31-33, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27692161

RESUMEN

Nausea and vomiting of pregnancy (NVP) remains difficult to treat. Last century, thalidomide was used to alleviate NVP, but it caused teratogenesis by interfering with angiogenesis. The gasotransmitters hydrogen sulfide (H2S) and nitric oxide are mutually dependent on each other for their angiogenesis-related functions. Pregnancy-related requirements for increased endogenous H2S could create a temporary excess of sulfite, an H2S catabolite, which is toxic and can induce nausea. Sulfite oxidase, a molybdenum-containing enzyme, catalyzes oxidation of sulfite to sulfate, which can then be excreted or reused by the body. Supplementation with molybdenum should facilitate enhanced sulfite oxidase activity, thus lowering gestationally-elevated sulfite levels in the gastrointestinal tract and easing NVP.


Asunto(s)
Molibdeno/uso terapéutico , Náuseas Matinales/terapia , Náusea/terapia , Sulfitos/efectos adversos , Catálisis , Femenino , Humanos , Sulfuro de Hidrógeno/química , Modelos Teóricos , Neovascularización Patológica , Óxido Nítrico/química , Oxígeno/química , Embarazo , Fosfato de Piridoxal/química , Sulfitos/química , Oligoelementos
15.
Eur J Obstet Gynecol Reprod Biol ; 197: 78-82, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26708475

RESUMEN

OBJECTIVE: To assess the comparative cost effectiveness of day care over inpatient management of nausea and vomiting of pregnancy (NVP). STUDY DESIGN: A cost utility analysis was performed using a decision analytical model in which a Markov model was constructed. The Markov model was primarily populated with data from a recently published randomised controlled trial. Which included pregnant women presenting to Cork University Maternity Hospital, a tertiary referral maternity hospital, seeking treatment for NVP. Costs and outcomes were estimated from the perspective of the Irish health service (HSE) and patients. A probabilistic sensitivity analysis, using a Monte Carlo simulation, was also performed. A Bayesian Value of Information analysis was used to estimate the value of collecting additional information. RESULTS: When both the healthcare provider and patient's perspective was considered, day care management of NVP remained less costly (mean €985; 95% C.I. 705-1456 vs. €3837 (2124-8466)) and more effective (9.42; 4.19-12.25 vs. 9.49; 4.32-12.39 quality adjusted life years) compared with inpatient management. The Cost Effectiveness Acceptability Curve indicates the probability that day care management is 70% more cost effective compared to inpatient management at a ceiling ratio of €45,000 per QALY, indicating little decision uncertainty. The Bayesian Value of Information analysis indicates there is value in collecting further information; the Expected Value of Perfect Information (EVPI) is estimated to be €5.4 million. CONCLUSION: Day care management of NVP is cost effective compared to inpatient management.


Asunto(s)
Atención Ambulatoria/métodos , Centros de Día/métodos , Hospitalización/economía , Hiperemesis Gravídica/terapia , Años de Vida Ajustados por Calidad de Vida , Adulto , Atención Ambulatoria/economía , Análisis Costo-Beneficio , Centros de Día/economía , Manejo de la Enfermedad , Femenino , Humanos , Hiperemesis Gravídica/economía , Irlanda , Cadenas de Markov , Náuseas Matinales/economía , Náuseas Matinales/terapia , Náusea/economía , Náusea/terapia , Embarazo , Vómitos/economía , Vómitos/terapia
18.
Cochrane Database Syst Rev ; (9): CD007575, 2015 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-26348534

RESUMEN

BACKGROUND: Nausea, retching and vomiting are very commonly experienced by women in early pregnancy. There are considerable physical, social and psychological effects on women who experience these symptoms. This is an update of a review of interventions for nausea and vomiting in early pregnancy last published in 2014. OBJECTIVES: To assess the effectiveness and safety of all interventions for nausea, vomiting and retching in early pregnancy, up to 20 weeks' gestation. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register, the Cochrane Complementary Medicine Field's Trials Register (19 January 2015) and reference lists of retrieved studies. SELECTION CRITERIA: All randomised controlled trials of any intervention for nausea, vomiting and retching in early pregnancy. We excluded trials of interventions for hyperemesis gravidarum, which are covered by another Cochrane review. We also excluded quasi-randomised trials and trials using a cross-over design. DATA COLLECTION AND ANALYSIS: Four review authors, in pairs, reviewed the eligibility of trials and independently evaluated the risk of bias and extracted the data for included trials. MAIN RESULTS: Forty-one trials involving 5449 women, met the inclusion criteria. These trials covered many interventions, including acupressure, acustimulation, acupuncture, ginger, chamomile, lemon oil, mint oil, vitamin B6 and several antiemetic drugs. There were no included studies of dietary and other lifestyle interventions. Evidence regarding the effectiveness of P6 acupressure, auricular (ear) acupressure and acustimulation of the P6 point was limited. Acupuncture (P6 or traditional) showed no significant benefit to women in pregnancy. The use of ginger products may be helpful to women, but the evidence of effectiveness was limited and not consistent, though three recent studies support ginger over placebo. There was only limited evidence from trials to support the use of pharmacological agents including vitamin B6, Doxylamine-pyridoxoine and other anti-emetic drugs to relieve mild or moderate nausea and vomiting. There was little information on maternal and fetal adverse outcomes and on psychological, social or economic outcomes.We were unable to pool findings from studies for most outcomes due to heterogeneity in study participants, interventions, comparison groups, and outcomes measured or reported. The methodological quality of the included studies was mixed. Risk of bias was low related to performance bias, detection bias and attrition bias for most studies. Selection bias risk was unclear for many studies and almost half of the studies did not fully or clearly report all pre-specified outcomes. AUTHORS' CONCLUSIONS: Given the high prevalence of nausea and vomiting in early pregnancy, women and health professionals need clear guidance about effective and safe interventions, based on systematically reviewed evidence. There is a lack of high-quality evidence to support any particular intervention. This is not the same as saying that the interventions studied are ineffective, but that there is insufficient strong evidence for any one intervention. The difficulties in interpreting and pooling the results of the studies included in this review highlight the need for specific, consistent and clearly justified outcomes and approaches to measurement in research studies.


Asunto(s)
Náusea/terapia , Complicaciones del Embarazo/terapia , Vómitos/terapia , Terapia por Acupuntura/métodos , Antieméticos/uso terapéutico , Femenino , Zingiber officinale/química , Humanos , Náuseas Matinales/etiología , Náuseas Matinales/terapia , Náusea/etiología , Fitoterapia/métodos , Embarazo , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento , Vitamina B 6/uso terapéutico , Complejo Vitamínico B/uso terapéutico , Vómitos/etiología
19.
Obstet Gynecol ; 126(3): 687-688, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26287781

RESUMEN

Nausea and vomiting of pregnancy is a common condition that affects the health of the pregnant woman and her fetus. It can diminish the woman's quality of life and also significantly contributes to health care costs and time lost from work (1, 2). Because "morning sickness" is common in early pregnancy, the presence of nausea and vomiting of pregnancy may be minimized by obstetricians, other obstetric providers, and pregnant women and, thus, undertreated (1). Furthermore, some women do not seek treatment because of concerns about safety of medications (3). Once nausea and vomiting of pregnancy progresses, it can become more difficult to control symptoms; treatment in the early stages may prevent more serious complications, including hospitalization (4). Mild cases of nausea and vomiting of pregnancy may be resolved with lifestyle and dietary changes, and safe and effective treatments are available for more severe cases. The woman's perception of the severity of her symptoms plays a critical role in the decision of whether, when, and how to treat nausea and vomiting of pregnancy. In addition, nausea and vomiting of pregnancy should be distinguished from nausea and vomiting related to other causes. The purpose of this document is to review the best available evidence about the diagnosis and management of nausea and vomiting of pregnancy.


Asunto(s)
Hiperemesis Gravídica/terapia , Náuseas Matinales/terapia , Náusea/terapia , Guías de Práctica Clínica como Asunto , Vómitos/terapia , Comités Consultivos/normas , Medicina Basada en la Evidencia , Femenino , Humanos , Hiperemesis Gravídica/diagnóstico , Náuseas Matinales/diagnóstico , Náusea/etiología , Náusea/fisiopatología , Embarazo , Estados Unidos , Vómitos/etiología , Vómitos/fisiopatología
20.
Harefuah ; 154(11): 720-4, 741, 2015 Nov.
Artículo en Hebreo | MEDLINE | ID: mdl-26821506

RESUMEN

Nausea and vomiting of pregnancy (NVP) is the most prevalent medical condition during gestation. Approximately 85% of pregnant women suffer from some degree of this condition, while hyperemesis gravidarum (HG), the most severe form, affects up to 2% of women. Although being the leading cause for hospitalization during pregnancy, NVP has received little attention from the medical community. NVP negatively affects women's quality of life, household activity and work productivity. In Canada, the financial cost of NVP, ranges from $132 to $653 per woman/week. In extreme cases, severe NVP results in therapeutic abortions. On the other hand, NVP has been shown to have a protective effect against spontaneous abortions and congenital malformations. Lately, there has been an interest in the hypothesis that NVP is a mechanism protecting the fetus from phytochemicals. Early treatment can prevent future complications and deterioration of the symptoms. Various studies have demonstrated the effectiveness and safety of antiemetic therapy in pregnancy. However, fear of teratogenicity and lack of clinical guidelines lead to trial and error NVP management. We present an updated algorithm for the management of NVP.


Asunto(s)
Antieméticos/uso terapéutico , Hiperemesis Gravídica/terapia , Náuseas Matinales/terapia , Antieméticos/efectos adversos , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Hiperemesis Gravídica/epidemiología , Náuseas Matinales/epidemiología , Embarazo , Prevalencia , Calidad de Vida , Índice de Severidad de la Enfermedad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...